Ivonescimab outperforms pembrolizumab as frontline therapy in PD-L1+ advanced NSCLC, OncLive (2024) Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial, The Lancet (2023) Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema, Reuters (2024) Vertex announces FDA acceptance of new drug application for suzetrigine for the treatment of moderate-to-severe acute pain, Vertex Pharmaceuticals Incorporated (2024) VX-548 in the treatment of acute pain, Pain Management (2024) Enhertu granted Priority Review in the U.S
Sultan A, Steven D, Rostock T, et al
How These Peptides Work in the Body Potential Risks, Side Effects and Safety Concerns Legal and Regulatory Status in the UK What UK Guidance Says About Unapproved Peptides Safer Alternatives and When to Seek Medical Advice Scientific References Frequently Asked Questions What Are CJC 1295, Ipamorelin and Retatrutide
doi: 10.1111/j.1348-0421.1999.tb02474.x 29 ClaverysJ